NeuroSense plans PrimeC new drug filing with Health Canada for ALSPUBT·2 days ago, 07:31 AMNRSN-8.08%
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" | NRSN Stock NewsStockTitan·Jul 5 at 11:45 PMNRSN-8.08%
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS | NRSN Stock NewsStockTitan·Jun 29 at 12:30 AMNRSN-8.08%
NeuroSense Posts Positive Phase 2 Biomarker Signals for PrimeC in Alzheimer’s TrialTip Ranks·Jun 25 at 08:50 AMNRSN-8.08%
NeuroSense joins EverythingALS community event on PrimeC data in ALSPUBT·Jun 22 at 08:03 AMNRSN-8.08%
